Exelixis (EXEL) reported late Tuesday Q1 non-GAAP earnings of $0.26 per diluted share, compared with $0.09 a year earlier. Analysts polled by Capital IQ...
...
...
Expected Earnings Release: 05/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $7,478,822 Exelixis Inc (EXEL) is due to issue its quarterly earnings...
| Address | 1851 Harbor Bay Parkway Alameda, California 94502 |
| Phone | +1.650.837.7000 |
| Number of Employees | 484 |
| Recent SEC Filing | 05/17/2022 4 |
| President, Chief Executive Officer & Director | Michael M. Morrissey |
| Executive Vice President-Business Operations | Dana T. Aftab |
| Chief Financial Officer & Executive Vice President | Christopher J. Senner |
| Chief Scientific Officer & EVP-Scientific Strategy | Peter Lamb |
| Price Open | $17.61 |
| Previous Close | $17.75 |
| 52 Week Range | $15.50 - 24.69 |
| Market Capitalization | $5.7 B |
| Shares Outstanding | 320.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 19.30 |
| Earnings per Share | $0.92 |
| Beta vs. S&P 500 | N/A |
| Revenue | $845.7 M |
| Net Profit Margin | 19.60% |
| Return on Equity | 13.77% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
